Active, not recruitingNCT05297812

Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease

Studying Alpha-1-antitrypsin deficiency

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Columbia University
Principal Investigator: Jeanine M D'Armiento, MD, PhD
Columbia University
Enrollment: 286 enrolled
Eligibility: 18 years · All sexes
Timeline: 2022 – 2027

Study locations (9)

University of Alabama at Birmingham, Birmingham, Alabama, United States
University of California - Los Angeles, Los Angeles, California, United States
National Jewish Health, Denver, Colorado, United States
University of Chicago, Chicago, Illinois, United States
Boston University, Boston, Massachusetts, United States
Columbia University, New York, New York, United States
University of North Carolina, Chapel Hill, North Carolina, United States
Medical University of South Carolina, Charleston, South Carolina, United States
University of Utah, Salt Lake City, Utah, United States

Collaborators

Alpha-1 Foundation · National Heart, Lung, and Blood Institute (NHLBI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05297812 on ClinicalTrials.gov

Other trials for Alpha-1-antitrypsin deficiency

Additional recruiting or active studies for the same condition.

See all trials for Alpha-1-antitrypsin deficiency →

← Back to all trials